EXHIBIT
99.01





Sangui
BioTech International , Inc.


1393
North Bennett Circle


Farmington,
Utah 84025




c/o
Sangui BioTech Gmbh


Alfred-Herrhausen-Str.
44


58455
Witten




State
of Tamaulipas (Mexico) starts clinical study involving Sangui wound management
system
  Witten,
Germany, December 11, 2008 – Sanguis BioTech Latino América and the Servicios de
Salud de Tamaulipas, the Mexican State of Tamaulipas Health Authority have
started a clinical study regarding the treatment of chronic wounds at the Civil
Hospital "Dr. José Macia Hernadez" in Ciudad Victoria, the capital of
Tamaulipas. According to an agreement signed to this effect December 4, 2008, a
total of 80 patients suffering from chronic wounds will be treated competitively
in groups of 40 patients each either according to the classic medical wound
therapies or according to the wound management system as developed by
SanguiBioTech. Signing the contract on behalf of the State of Tamaulipas were
the Minister of Health Sr. Dr. Rodolfo Torre Cantu, the Under Secretary of State
Sr. Amerigo Villareal Anaya, as well as the Managing Director of the Hospital
Sr. Dr. Jesus Flores Robles.
  Mexico is
suffering from the second largest diabetes rate in the world, spending more than
US $ 30.000.000.000 per year to fight its dire consequences. A special area of
the Hospital Dr. Hernadez has been dedicated to those treatments, and special
equipment for measurements, evaluation and supervision was installed. Results of
the treatments will be measured against a joint medical protocol. The treatments
were started immediately; initial results are expected to be available by the
end of the first quarter of 2009.
  On the
occasion of the signing of the contract representatives of the Tamaulipas Health
Authorities expressed their confidence that a success of the Sangui system will
help hundreds of thousands of Mexican citizens to find relief from yearlong
sufferings and to regain their quality of life. They underlined that also the
entire public health system would benefit substantially from implementing an
effective system for healing chronic wounds by way of substantial cost savings.
Eduardo Mena, CEO of Sanguis BioTech Latino América, said: "Together with our
German partners, we have invested heavily to show the Mexican people and its
authorities that this major health problem can be tackled successfully. So, we
are excited about the opportunity to put the Sangui system to an official test,
where we can demonstrate the efficiency of our innovative
approach."
  Having
acted as a co-signatory to the agreement, Hubertus Schmelz, Managing Director of
SanguiBioTech GmbH, was impressed by the attention paid to this test by numerous
high ranking officials: "Evidently, there is a strong awareness of the benefits
to be gained from our wound management system. Our partners at Sangui LA have
done a great job to demonstrate its potential and hence to attract the
commitment of the Public Health System to actually implement it in case the
results are as expected."
  SanguiBioTech
GmbH is a subsidiary of Sangui Biotech International, Inc.
 (www.pinksheets.com:
SGBI)
  For more
information please contact:
  Joachim
Fleing
 Phone:
+49 (160) 741 27 17
 Fax: +49
(2302) 915 191
 e-mail:
fleing@sangui.de
  Forward
Looking Statements
  Some of
the statements contained in this news release discuss future expectations,
contain projections of results of operation or financial condition or state
other “forward-looking” information. These statements are subject to known and
unknown risks, uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the statements. The
forward-looking information is based on various factors and is derived using
numerous assumptions. Important factors that may cause actual results to differ
from projections include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as “anticipates,”
“expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations
of such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or
otherwise.